var data={"title":"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/contributors\" class=\"contributor contributor_credentials\">Josef T Prchal, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/contributors\" class=\"contributor contributor_credentials\">Stanley L Schrier, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/contributors\" class=\"contributor contributor_credentials\">Alan G Rosmarin, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 06, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Absolute polycythemia refers to settings in which there is an increase in red cell mass. This condition has also been called erythrocytosis, with three forms being recognized (<a href=\"image.htm?imageKey=HEME%2F76036\" class=\"graphic graphic_table graphicRef76036 \">table 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Primary polycythemia</strong> &ndash; Primary polycythemia is caused by acquired (somatic) or inherited (germline) mutations expressed within the erythroid progenitors that increase their proliferation and cause accumulation of erythrocytes (ie, polycythemia). Such mutations occur in polycythemia vera and in dominantly inherited polycythemias caused by &quot;gain-of-function&quot; mutations of the erythropoietin receptor gene (<em>EPOR</em>). Primary polycythemias can be distinguished from secondary polycythemias by in vitro assays that reveal proliferation of erythroid progenitors with minimal or no added erythropoietin (EPO).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Secondary polycythemia</strong> &ndash; Secondary polycythemia refers to conditions in which there are circulating plasma factors that stimulate erythropoiesis (eg, EPO, testosterone). In rare instances, exposure to cobalt, dysregulated <span class=\"nowrap\">angiotensin/angiotensin</span> receptor 1 erythroid signaling (eg, in postrenal transplant erythrocytosis), or elevated plasma levels of insulin-like growth factor-1 can stimulate erythropoiesis.</p><p/><p class=\"bulletIndent1\">Secondary polycythemia can be &quot;appropriate&quot; or &quot;inappropriate&quot; physiological responses, and both categories include both acquired and congenital causes. Examples include appropriate physiological response to tissue hypoxia (eg, low hemoglobin oxygen saturation from lung disease, high carboxy-hemoglobin in cigarette smokers) or congenital causes (eg, mutant hemoglobin with increased oxygen affinity; inherited defect of 2,3 BPG [2,3 DPG] synthesis). Examples of inappropriate responses include EPO-secreting tumors or increased EPO due to congenital disorders of hypoxia sensing. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mixed (ie, primary and secondary) congenital disorders of hypoxia sensing</strong> &ndash; Some disorders share features of both primary (ie, increased sensitivity of erythroid progenitors to EPO) and secondary polycythemia (ie, elevated EPO levels). Examples include Chuvash polycythemia, other congenital von Hippel Lindau (<em>VHL</em>) gene mutations, and gain-of-function mutations of <em>EPAS1</em> (encoding hypoxia inducible factor HIF-2 alpha). </p><p/><p class=\"bulletIndent1\">Another congenital disorder of hypoxia sensing, loss-of-function mutation of <em>EGLN1</em> (encoding proline hydroxylase 2) is incompletely characterized.</p><p/><p>Congenital polycythemias with established molecular lesions due to germline mutations that either modify hemoglobin oxygen affinity or modify the normal response to hypoxia will be discussed here. Current understanding of the molecular pathogenesis of polycythemia vera will also be discussed here. The clinical approaches to the patient with polycythemia or suspected polycythemia vera are discussed separately. (See <a href=\"topic.htm?path=diagnostic-approach-to-the-patient-with-polycythemia\" class=\"medical medical_review\">&quot;Diagnostic approach to the patient with polycythemia&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polycythemia-vera\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of polycythemia vera&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">REGULATION OF ERYTHROPOIESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Erythropoiesis is the physiologic process involved in the production and renewal of the red blood cell mass. A brief review of the basic aspects of erythropoiesis is presented below to allow for a better understanding of the potential mechanisms by which polycythemia can occur.</p><p>A more detailed discussion of the regulation of this process is presented separately. (See <a href=\"topic.htm?path=regulation-of-erythropoiesis\" class=\"medical medical_review\">&quot;Regulation of erythropoiesis&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Erythropoietin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The principal hormone that regulates erythropoiesis is erythropoietin (EPO) which, in adults, is primarily secreted by the kidney and, to a lesser degree, by the liver. Variable levels of EPO are required at the different stages of erythroid maturation [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/1\" class=\"abstract_t\">1</a>]. It is most important for terminal maturation of erythroid cells at the level of the early BFU-E (burst-forming-units erythroid) and late committed erythroid progenitors (ie, CFU-E [colony-forming units erythroid]) during adult erythropoiesis. Thus, mice with homozygous null mutations of the <em>EPO</em> or EPO receptor (<em>EPOR</em>) form early erythroid progenitors that fail to differentiate into mature erythrocytes and die [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/2\" class=\"abstract_t\">2</a>].</p><p>In comparison, the pluripotent stem cells and early progenitor cells require stem cell factor, thrombopoietin, granulocyte-macrophage colony-stimulating factor (GM-CSF), <span class=\"nowrap\">and/or</span> interleukin (IL)-3 for growth in addition to EPO (<a href=\"image.htm?imageKey=HEME%2F70092\" class=\"graphic graphic_figure graphicRef70092 \">figure 1</a>). </p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Oxygen sensor</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The major stimulus for EPO production is decreased oxygen delivery due to reduced red blood cell mass (anemia) or decreased O2 saturation of hemoglobin (hypoxemia), as described in the following paragraphs [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/3-6\" class=\"abstract_t\">3-6</a>]. (See <a href=\"topic.htm?path=regulation-of-erythropoiesis#H19\" class=\"medical medical_review\">&quot;Regulation of erythropoiesis&quot;, section on 'Hypoxia-inducible factor and the response to hypoxia'</a>.)</p><p>Hypoxic stimulation of the oxygen sensor-signaling pathway results in increased production of hypoxia inducible factors (HIF-1 and HIF-2). HIF-2 is the major enhancer for <em>EPO</em> gene transcriptional activation [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/7\" class=\"abstract_t\">7</a>]. Protein levels of HIF-1 and HIF-2 alpha subunits are stabilized by hypoxia and decay rapidly in normoxia [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/8\" class=\"abstract_t\">8</a>].</p><p>HIF-1 and HIF-2 are essential for life; they play an important role in cellular adaptation to hypoxia by controlling transcription of <em>EPO</em> and many genes that are essential for erythropoiesis and other functions, including vascular endothelial growth factor (VEGF) and its receptor, energy metabolism (ie, the glucose transporter and glycolytic enzymes), iron metabolism (ie, hepcidin and transferrin receptor), and cellular development. HIFs also play a major role in cancer and facilitate the unique energy metabolism of cancer cells, known as the Warburg effect [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/9\" class=\"abstract_t\">9</a>].</p><p>HIF-alpha subunit isoforms (HIF-1 alpha, HIF-2 alpha, HIF-3 alpha) are rapidly destroyed in the presence of oxygen by a mechanism that involves prolyl hydroxylation (by prolyl hydroxylases enzymes), followed by the binding to the VHL tumor suppressor protein (pVHL), which leads to their ubiquitylation and proteasomal degradation by E3 ligase complex. This process is suppressed by hypoxia and iron chelation and regulated by a proline hydroxylase enzyme. This complex constitutes a cellular oxygen sensor (<a href=\"image.htm?imageKey=HEME%2F53801\" class=\"graphic graphic_figure graphicRef53801 \">figure 2</a>) and mutations along this pathway have been associated with various polycythemic conditions [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/3,4,10\" class=\"abstract_t\">3,4,10</a>]. (See <a href=\"#H11\" class=\"local\">'EGLN1 gene mutations'</a> below and <a href=\"#H10\" class=\"local\">'von Hippel Lindau gene mutation'</a> below and <a href=\"#H12\" class=\"local\">'EPAS1 (hypoxia inducible factor 2) gene mutations'</a> below.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Erythropoietin receptor</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The effect of EPO on progenitor cells is mediated by a specific receptor (EPOR) [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/11\" class=\"abstract_t\">11</a>]. The interaction of EPO with its receptor leads to conformational changes of EPOR homodimers and signal transduction that result in:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stimulation of mitogenicity (proliferation) of erythroid progenitor cells.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Differentiation by induction of erythroid-specific expression of proteins.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prevention of apoptosis of erythroid progenitors [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/12\" class=\"abstract_t\">12</a>].</p><p/><p>The cytoplasmic portion of the EPOR distal to the transmembrane domain is a <strong>positive</strong> regulatory domain [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/13\" class=\"abstract_t\">13</a>] that interacts with Janus 2 tyrosine kinase (JAK2). Immediately after EPO binding, JAK2 phosphorylates itself, the EPOR, and the STAT5 transcription factor, initiating a cascade of erythroid-specific signaling and prevention of apoptosis [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/14\" class=\"abstract_t\">14</a>].</p><p>On the other hand, even more distal, the C-terminal cytoplasmic portion of the EPOR functions as a <strong>negative</strong> regulatory domain [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/13\" class=\"abstract_t\">13</a>]. Hematopoietic cell phosphatase (HCP, also called SH protein tyrosine phosphatase, SHP-1, and SH-PTP1) interacts with this portion of the EPOR and downregulates signal transduction [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/15\" class=\"abstract_t\">15</a>]. Mutants lacking this portion of the EPOR are hypersensitive to EPO and display prolonged EPO-induced autophosphorylation of JAK2 and increased proliferation of erythroid progenitor cells [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/15\" class=\"abstract_t\">15</a>].</p><p>Thus far, only gain-of-function <em>EPOR</em> mutations have been demonstrated in patients with primary familial and congenital polycythemia [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/16-18\" class=\"abstract_t\">16-18</a>]. All <em>EPOR</em> gene mutations associated with this disorder lead to a truncated receptor that lacks the C-terminal negative regulatory domain of the receptor [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/18,19\" class=\"abstract_t\">18,19</a>]. (See <a href=\"#H8\" class=\"local\">'Congenital polycythemias with augmented hypoxia sensing'</a> below.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Insulin-like growth factor-I</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many of the in vitro studies that provided information about the hierarchy of regulation of erythropoiesis were performed in the presence of serum and serum-component proteins that might stimulate or inhibit erythropoiesis. One such stimulator is insulin-like growth factor-I (IGF-I), which has EPO-like activity that targets circulating early erythroid progenitors [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/20,21\" class=\"abstract_t\">20,21</a>].</p><p>IGF-I is likely also important in patients with end-stage renal disease. Some of these patients have normal hematocrit that cannot be correlated with serum EPO concentrations. Serum IGF-I is increased in such patients and the serum stimulates marrow BFU-E and CFU-E growth via an effect that is partially blocked by anti-IGF-I antibodies [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/22\" class=\"abstract_t\">22</a>]. Similar observations have been made in patients with post-renal transplant erythrocytosis. (See <a href=\"topic.htm?path=erythrocytosis-following-renal-transplantation\" class=\"medical medical_review\">&quot;Erythrocytosis following renal transplantation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Angiotensin II</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The evidence for a role of angiotensin II in the regulation of erythropoiesis comes mainly from the well described therapeutic effect of angiotensin converting enzyme (ACE) inhibitors and the specific angiotensin II type 1 (AT1) receptor blocker <a href=\"topic.htm?path=losartan-drug-information\" class=\"drug drug_general\">losartan</a> on erythrocytosis following renal transplantation [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/23,24\" class=\"abstract_t\">23,24</a>]. In addition, ACE inhibitors can induce a mild, reversible anemia in some renal transplant recipients without erythrocytosis and can increase EPO requirements in some patients on hemodialysis [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/25,26\" class=\"abstract_t\">25,26</a>]. (See <a href=\"topic.htm?path=erythrocytosis-following-renal-transplantation\" class=\"medical medical_review\">&quot;Erythrocytosis following renal transplantation&quot;</a>.)</p><p>AT1 receptor has been identified on erythroid progenitors, suggesting that angiotensin II may play a direct role in the regulation of erythropoiesis [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/27\" class=\"abstract_t\">27</a>]. The observation that angiotensin II intracellular transduction includes JAK2 kinase [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/28\" class=\"abstract_t\">28</a>], an enzyme that plays an important role in EPO signaling, suggests the possibility of a shared signal transduction pathway between EPO and angiotensin II. It is therefore possible that some of the as yet uncharacterized genotypes of familial and congenital polycythemias could be due to alterations in angiotensin <span class=\"nowrap\">II/AT1</span> receptor signaling. </p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">CONGENITAL POLYCYTHEMIAS WITH AUGMENTED HYPOXIA SENSING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypoxia sensing is central to the regulation of many physiological functions and to regulating transcription of many known and yet to be elucidated genes [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/5,29\" class=\"abstract_t\">5,29</a>]. The following disorders with mutations in hypoxia-sensing pathways (HIF dysregulation) were identified because of the presence of an elevated hematocrit [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/19\" class=\"abstract_t\">19</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chuvash polycythemia and other <em>VHL</em> gene mutations </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Loss-of-function mutations of <em>EGLN1</em> (encoding proline hydroxylase 2 [PHD2])</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gain-of-function mutations of <em>EPAS1</em> (encoding HIF-2 alpha) </p><p/><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Chuvash polycythemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The primary and secondary congenital polycythemias occur sporadically, without a seeming predilection for a particular population. In contrast, Chuvash polycythemia is a form of congenital polycythemia that is endemic in the Chuvash population of the Russian Federation (mid-Volga region of European Russia) [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/30-32\" class=\"abstract_t\">30-32</a>], and another endemic locus of Chuvash polycythemia has been reported in the Southern Italian island of Ischia, with a gene frequency even higher than that in the Chuvash Autonomous Republic [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/33\" class=\"abstract_t\">33</a>]. This mutation has now been reported worldwide, albeit occurring sporadically [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/34,35\" class=\"abstract_t\">34,35</a>], and in most instances presents on the same <em>VHL</em> haplotype, indicating an origin from the same founder [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/36\" class=\"abstract_t\">36</a>].</p><p>Chuvash polycythemia causes thrombotic and hemorrhagic vascular complications that lead to early mortality, usually before the age of 40 years [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/37,38\" class=\"abstract_t\">37,38</a>]. The serum EPO concentration in polycythemic patients is elevated or inappropriately normal for the given elevation of the hematocrit [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/37,39\" class=\"abstract_t\">37,39</a>] and serum hepcidin levels are reduced [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/40\" class=\"abstract_t\">40</a>], consistent with results showing that the HIF pathway is engaged in coordinate regulation of iron metabolism and erythropoiesis through upregulation of EPO and downregulation of hepcidin [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/41\" class=\"abstract_t\">41</a>]. Intermittent phlebotomy, <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, <span class=\"nowrap\">and/or</span> antihistamines are commonly used based on data extrapolated from patients with polycythemia vera [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/38\" class=\"abstract_t\">38</a>]; however, this practice is not warranted as the phlebotomies increase rate of thrombotic complications [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/42\" class=\"abstract_t\">42</a>]. The erythrocyte progenitors are hypersensitive to EPO [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/39\" class=\"abstract_t\">39</a>], a finding that blurs the distinction between primary and secondary polycythemia [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/9\" class=\"abstract_t\">9</a>]. In one report, the JAK2 inhibitor <a href=\"topic.htm?path=ruxolitinib-drug-information\" class=\"drug drug_general\">ruxolitinib</a> resulted in decreased phlebotomy requirements in three patients with Chuvash polycythemia [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/43\" class=\"abstract_t\">43</a>]. </p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">von Hippel Lindau gene mutation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A causative mechanism in Chuvash polycythemia (CP) established it as the first recognized congenital abnormality in the oxygen-sensing pathway [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/44\" class=\"abstract_t\">44</a>], due to a constitutive up-regulation of HIF1 and HIF2 alpha subunits in this disease [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/39\" class=\"abstract_t\">39</a>]. (See <a href=\"topic.htm?path=regulation-of-erythropoiesis#H18\" class=\"medical medical_review\">&quot;Regulation of erythropoiesis&quot;, section on 'Hypoxia and EPO expression'</a>.)</p><p>The CP gene was localized by positional cloning to a mutation of the von Hippel-Lindau (<em>VHL</em>) gene found in both alleles of all CP patients and in one allele of all CP carriers [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/39\" class=\"abstract_t\">39</a>]. This is a somewhat surprising finding, since the tumors that occur by somatic mutation in &ldquo;<em>VHL</em> tumor predisposition syndrome&rdquo;, (ie, pheochromocytoma, renal cell carcinoma, and hemangioblastomas) are not seen in patients with CP or their heterozygous relatives, although, on the other hand, the latter tumors can be associated with acquired polycythemia. This has been attributed, at least in part, to the degree of the mutation&rsquo;s interference with the inhibition of the hypoxia signaling pathway [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/45\" class=\"abstract_t\">45</a>]. (See <a href=\"topic.htm?path=molecular-biology-and-pathogenesis-of-von-hippel-lindau-disease\" class=\"medical medical_review\">&quot;Molecular biology and pathogenesis of von Hippel-Lindau disease&quot;</a> and <a href=\"topic.htm?path=diagnostic-approach-to-the-patient-with-polycythemia#H24\" class=\"medical medical_review\">&quot;Diagnostic approach to the patient with polycythemia&quot;, section on 'Tumor polycythemia'</a>.)</p><p>There is a growing list of other homozygous and compound heterozygous germline <em>VHL</em> gene mutations other than Chuvash <em>VHL </em>R200W that are associated with polycythemia and not with VHL tumor syndrome. These include Croatian polycythemia due to <em>VHL </em>H191D<em><sup> </sup></em>mutation [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/46\" class=\"abstract_t\">46</a>], <em>VHL</em> exon 2 mutation <em>VHL </em>P138L [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/47\" class=\"abstract_t\">47</a>], and other compound VHL gene heterozygous germline mutations <em>VHL </em>T124A and <em>VHL </em>L188V [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/48\" class=\"abstract_t\">48</a>].</p><p>However, most of the mutations of <em>VHL</em> genes are associated with tumors characteristic of <em>VHL</em> tumor predisposition syndrome and not congenital polycythemia, although in some instances an acquired polycythemia from the EPO produced by tumor is encountered [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/49\" class=\"abstract_t\">49</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">EGLN1 gene mutations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mutations in the <em>EGLN1</em> gene, encoding PHD2 (prolyl hydroxylase domain protein 2), involved in the degradation of HIF-alpha under normoxic conditions, are associated with autosomal dominant erythrocytosis [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/50\" class=\"abstract_t\">50</a>]. As an example, a study of 67 patients with spontaneous or familial isolated erythrocytosis identified three novel mutations in the catalytic domain of the PHD2 protein [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/51\" class=\"abstract_t\">51</a>]. All were germ-line, heterozygous, and missense loss-of-function mutations, and coded for a predicted full-length mutant PHD2 protein [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/5\" class=\"abstract_t\">5</a>]. A non-erythroid phenotype of these mutations has not yet been defined.</p><p>An orally active inhibitor of HIF-prolyl hydroxylase has been shown to increase EPO production and stimulate erythropoiesis in mouse and primate models [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/52\" class=\"abstract_t\">52</a>], and conditional inactivation or deletion of PHD2 in mice leads to erythrocytosis [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/53,54\" class=\"abstract_t\">53,54</a>]. Such inhibitors are currently being tested in the clinical setting as a potential treatment for anemia, including anemia secondary to chronic renal disease [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/55,56\" class=\"abstract_t\">55,56</a>]. However, as PHD2 manipulations activate many other genes, such inhibitors might have unintended deleterious effects [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/56,57\" class=\"abstract_t\">56,57</a>]. (See <a href=\"topic.htm?path=introduction-to-recombinant-hematopoietic-growth-factors#H20\" class=\"medical medical_review\">&quot;Introduction to recombinant hematopoietic growth factors&quot;, section on 'EPO mimetics'</a>.)</p><p>Of interest, a gain-of-function mutation of <em>EGLN1</em> (Asp4Glu; Cys127Ser) appears to contribute to the observed protection of Tibetans from the development of polycythemia at high altitude [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/58\" class=\"abstract_t\">58</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">EPAS1 (hypoxia inducible factor 2) gene mutations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Autosomal dominant erythrocytosis has been described in a number of families due to a gain-of-function germline mutation in the <em>EPAS1</em> gene (encoding HIF2-alpha), rendering the HIF2-alpha protein less susceptible to hydroxylation by PHD2 [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/59-62\" class=\"abstract_t\">59-62</a>]. Affected individuals usually present with congenital erythrocytosis and with elevated or inappropriately normal EPO levels considering their elevated hematocrit. While the relative contributions of HIF1-alpha and HIF2-alpha to hypoxia-driven gene expression of EPO is still an area of intense investigation [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/63\" class=\"abstract_t\">63</a>], the existence of these subjects substantiates a central role for HIF2-alpha in the regulation of EPO synthesis in humans [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/9\" class=\"abstract_t\">9</a>]. (See <a href=\"#H10\" class=\"local\">'von Hippel Lindau gene mutation'</a> above.)</p><p>A subset of patients with congenital polycythemia will develop recurrent pheochromocytomas, paragangliomas, and sometimes somatostatinomas [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/64\" class=\"abstract_t\">64</a>]. These novel HIF2-alpha mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/65\" class=\"abstract_t\">65</a>]. Their tumors are heterozygous for any of the gain-of-function mutation of the <em>EPAS1</em> gene, and erythropoietin transcript is present in the tumor. The mutations in all cases were in the vicinity of the primary hydroxylation site of the HIF2-alpha protein, leading to increased HIF2-alpha activity and increased protein half-life and upregulation of the hypoxia-related genes <em>EPO</em>, <em>VEGFA</em>, <em>GLUT1</em>, and <em>END1</em> in tumors [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/66\" class=\"abstract_t\">66</a>]. However, these mutations are generally not found in non-tumor tissues, so the etiology of the association of these tumors with polycythemia is unknown but suspected to result from embryonic mosaicism.</p><p>In another report, a polycythemic patient with a novel germline <em>EPAS1</em> gene<sup> </sup>mutation inherited from his mother also developed recurrent <span class=\"nowrap\">pheochromocytoma/paraganglioma</span> [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/67\" class=\"abstract_t\">67</a>]. This underscores the <span class=\"nowrap\">pheochromocytoma/paraganglioma-promoting</span> potential of gain-of-function mutations of <em>EPAS1</em> that alone, either as somatic or germline mutations, can contribute to, but are not sufficient for, <span class=\"nowrap\">pheochromocytoma/paraganglioma</span> development.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">OTHER POLYCYTHEMIAS WITH DEFINED MOLECULAR LESIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The other polycythemias with defined molecular lesions include the high oxygen affinity hemoglobin mutants, congenital methemoglobinemia, and 2,3-bisphosphoglycerate (2,3-BPG) deficiency. The first two disorders, which are associated with increased hemoglobin oxygen affinity, are discussed in detail elsewhere and will be only briefly reviewed here.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">High oxygen affinity hemoglobin mutants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Congenital polycythemias due to high oxygen affinity hemoglobin mutants were the first congenital polycythemias defined, but are an uncommon cause of congenital polycythemia. Mutations of both alpha and beta globin genes have been described that lead to autosomal dominant polycythemia. (See <a href=\"topic.htm?path=genetic-disorders-of-hemoglobin-oxygen-affinity\" class=\"medical medical_review\">&quot;Genetic disorders of hemoglobin oxygen affinity&quot;</a>.)</p><p>The hemoglobin tetramer oscillates between the R (relaxed; fully oxygenated hemoglobin) and T (tense; fully deoxygenated hemoglobin) states of the quaternary protein conformation, requiring the cooperative interaction of globin subunits. Single point substitutions, double point substitutions, deletions, insertions, reading frame shift mutations, and fusion genes can all result in hemoglobins with increased oxygen affinity [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/1\" class=\"abstract_t\">1</a>]. Underlying all known high ligand affinity hemoglobin mutants is the furtherance of the R state, or high affinity conformer of the hemoglobin molecule. This can occur by stabilizing the R state or destabilizing the T state (low affinity conformer). The molecular basis of this change can be:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alteration in areas of the molecule directly involved in the R&mdash;&gt;T transition, such as in Hb Chesapeake and Hb Montefiore</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A change of the alpha 1 beta 1 interface, such as in Hb Crete</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A mutation reducing the affinity of the hemoglobin for 2,3-BPG, such as is seen in Hb Rahere and Hb Providence</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Elongation of chains by termination codon or frame-shift mutations</p><p/><p>A complete listing of high affinity hemoglobins can be found on the Globin Gene Server on the Internet (<a href=\"http://globin.cse.psu.edu/&amp;token=W/MNZorEFI2EtNnE4Oqza+LSzyNbNNPsEL85T2QwNbbfeKuzf3vos5FVncGUXy64&amp;TOPIC_ID=7106\" target=\"_blank\" class=\"external\">globin.cse.psu.edu</a>).</p><p>The functional consequence of this change in oxygen affinity is decreased delivery of oxygen to the peripheral tissues and compensatory polycythemia. Regardless of the mechanism, affected patients are generally asymptomatic, since compensatory polycythemia appropriately maintains normal tissue oxygen delivery.</p><p>There is considerable variation in the age at diagnosis. The germline mutations of alpha-globin<em> </em>genes resulting in high oxygen affinity are associated with life-long polycythemia, while those of beta-globin genes are silent at birth, but polycythemia develops after fetal to adult hemoglobin switch at approximately six months of age. Among patients with polycythemia, a red cell defect, such as a high oxygen affinity hemoglobin, should be considered in those who have an inappropriately normal or an elevated serum EPO concentration and a normal partial pressure of oxygen and oxygen saturation. The hemoglobin oxygen dissociation curve is the benchmark for diagnosis. However, an accurate p50 value <strong>cannot</strong> be &quot;calculated&quot; from <strong>arterial</strong> pO2 data as is often done. Although not widely available, the hemox-analyzer apparatus is required when accurate p50 and Hill coefficients are needed [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/68\" class=\"abstract_t\">68</a>]. p50 can be estimated from venous blood gasses [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/69\" class=\"abstract_t\">69</a>]. The saturation of hemoglobin, pH, and pO2 from <strong>venous</strong> blood must be directly measured to estimate an informative p50 in these patients (<a href=\"image.htm?imageKey=HEME%2F81216\" class=\"graphic graphic_figure graphicRef81216 \">figure 3</a>), as verified in study of several high oxygen affinity hemoglobin mutants [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/69\" class=\"abstract_t\">69</a>]. (See <a href=\"topic.htm?path=genetic-disorders-of-hemoglobin-oxygen-affinity\" class=\"medical medical_review\">&quot;Genetic disorders of hemoglobin oxygen affinity&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Congenital methemoglobinemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>During the formation of oxyhemoglobin from deoxyhemoglobin and molecular oxygen, one electron is partially transferred from heme iron to the bound oxygen, forming a ferric-superoxide anion complex <span class=\"nowrap\">(Fe3+/O2-)</span>. During deoxygenation, most of the oxygen leaves the molecule as molecular oxygen, but a small amount leaves as a superoxide (O2-) radical. In the latter circumstance, the partially transferred electron is not returned to the iron moiety, leaving the iron in the ferric state and forming methemoglobin [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/2\" class=\"abstract_t\">2</a>]:</p><div class=\"formulaContainer\"><div class=\"formula\"><p> &#160;<span class=\"nowrap\">HbFe2+/O2</span> &#160; &mdash;&gt; &#160; HbFe3+ &#160; + &#160; O2-</p></div></div><p>Autooxidation of hemoglobin to methemoglobin occurs spontaneously at a slow rate in normal individuals, converting a small percent of the available hemoglobin to methemoglobin each hour. The only physiologically important pathway for reducing methemoglobin back to hemoglobin is the NADH-dependent reaction catalyzed by cytochrome b5 reductase (b5R). (See <a href=\"topic.htm?path=genetics-and-pathogenesis-of-methemoglobinemia\" class=\"medical medical_review\">&quot;Genetics and pathogenesis of methemoglobinemia&quot;</a>.)</p><p>The ferric hemes of methemoglobin are <strong>unable</strong> to bind oxygen. In addition, the oxygen affinity of any accompanying ferrous hemes in the hemoglobin tetramer is increased; as a result, the oxygen dissociation curve is &quot;left-shifted&quot; and oxygen delivery to the tissues is impaired, leading, in some affected individuals, to a compensatory polycythemia to maintain normal tissue oxygen delivery (<a href=\"image.htm?imageKey=HEME%2F81216\" class=\"graphic graphic_figure graphicRef81216 \">figure 3</a>) [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/70\" class=\"abstract_t\">70</a>].</p><p>The major cause of hereditary methemoglobinemia is a deficiency of cytochrome b5 reductase. Less common causes are hemoglobin M disease, in which there is a mutated globin, and cytochrome b5 deficiency. (See <a href=\"topic.htm?path=genetics-and-pathogenesis-of-methemoglobinemia\" class=\"medical medical_review\">&quot;Genetics and pathogenesis of methemoglobinemia&quot;</a>.)</p><p>Most patients with congenital methemoglobinemia from type I cytochrome b5 reductase or hemoglobin M disease are asymptomatic, although some complain of headache and easy fatigue, even with methemoglobin levels as high as 40 percent of total hemoglobin; however, those with less common type II cytochrome b5 reductase, have also deficient non-erythroid cells resulting in early death with array of severe developmental defects. Their main complaint is &quot;cyanosis&quot; or slate-blue color of the skin and mucous membranes, a finding that is due to the different absorbance spectrum of methemoglobin compared with oxyhemoglobin. The laboratory diagnosis of methemoglobinemia is based upon analysis of its absorption spectrum, which has peak absorbance at 631 nm. (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-methemoglobinemia\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of methemoglobinemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">2,3-bisphosphoglycerate deficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An extremely rare cause of congenital secondary polycythemia is familial 2,3-BPG (previously known as 2,3-DPG) deficiency, which results from a deficiency of the red cell enzyme bisphosphoglyceromutase (BPGM) [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/71-73\" class=\"abstract_t\">71-73</a>]. The ensuing increase in hemoglobin oxygen affinity decreases the amount of oxygen released peripherally, leading to compensatory polycythemia.</p><p>Only one family with this deficiency has been comprehensively studied [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/71-73\" class=\"abstract_t\">71-73</a>]. The proband with polycythemia had undetectable BPGM activity and 2,3-BPG levels; his children were not polycythemic, a finding compatible with an autosomal recessive disease. Subsequent studies have shown that the virtual absence of BPGM activity in the proband and three sisters was due to compound heterozygosity for mutations in the <em>BPGM</em> gene [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/73\" class=\"abstract_t\">73</a>]. However, the children had partially reduced enzyme activity and mildly decreased 2,3-BPG levels reflected in a reduced P50. Other heterozygous progeny of this enzyme-deficient patient, as well as several heterozygous subjects from unrelated families, were later found to have moderate polycythemia, casting doubt on the autosomal recessive mode of its inheritance [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/72\" class=\"abstract_t\">72</a>].</p><p>Because of the rarity of complete BPGM deficiency, it is not possible at this time to predict the phenotype of heterozygous individuals. Finding a decreased P50 is a prerequisite for consideration of 2,3-BPG deficiency as a cause of congenital polycythemia (<a href=\"image.htm?imageKey=HEME%2F81216\" class=\"graphic graphic_figure graphicRef81216 \">figure 3</a>). In comparison to the high oxygen affinity hemoglobins, the oxygen affinity of the dialyzed hemolysate is normal and the level of 2,3-BPG is very low in familial 2,3-BPG deficiency.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Primary familial and congenital polycythemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary familial and congenital polycythemia (PFCP, also called benign erythrocytosis and autosomal dominant erythrocytosis) is an uncommon cause of polycythemia but is more prevalent than 2,3-BPG deficiency. It is typically inherited as an autosomal dominant (or less frequently sporadic) disorder. Its characteristics are defined in greater detail elsewhere [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/16,18,74-76\" class=\"abstract_t\">16,18,74-76</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An elevated erythrocyte mass and hemoglobin concentration</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypersensitivity of erythroid progenitors to EPO in serum-containing clonogenic cultures</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Low serum EPO concentrations</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A normal hemoglobin-oxygen dissociation curve</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Absence of progression to acute leukemia</p><p/><p>All <em>EPOR</em> mutations associated with this disorder have a truncated receptor that lacks the C-terminal negative regulatory domain of the receptor [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/18,77\" class=\"abstract_t\">18,77</a>]. Thus, the lack of binding site for the negative regulator hematopoietic phosphatase (HCP) triggers <span class=\"nowrap\">proliferation-inducing/apoptosis-inhibiting</span> pathways that contribute to the polycythemia. Polycythemia was replicated in a mouse model in which the mouse gene was replaced by a disease-causing human <em>EPOR</em> gene [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/78\" class=\"abstract_t\">78</a>].</p><p>However, <em>EPOR</em> mutations are an infrequent cause of PFCP. In one analysis of 53 unrelated subjects, for example, only five <em>EPOR</em> mutations were identified (9 percent) [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/18,79\" class=\"abstract_t\">18,79</a>]. It has been suggested that a dominant lesion at an as yet unidentified gene, involving either the EPOR-signaling pathway or another erythropoiesis-regulating pathway, is responsible for the enhanced proliferation of erythroid progenitors in response to EPO in these patients.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">POLYCYTHEMIAS WITH INCOMPLETELY DEFINED MOLECULAR LESIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to patients with PFCP who do not have an <em>EPOR</em> gene mutation, the other major congenital polycythemias in which the molecular lesion is incompletely defined include those with congenital elevation of EPO and normal to increased responsiveness of erythroid progenitors to EPO.</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h1\">POLYCYTHEMIA VERA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polycythemia vera (PV) is the most common of the primary polycythemias. As with the other Philadelphia chromosome negative chronic myeloproliferative neoplasms (essential thrombocythemia and primary myelofibrosis), PV is often caused by more than one genetic event (either acquired somatic, another acquired somatic or inherited germline mutations) in a single hematopoietic progenitor that leads to an increase in red cell production and a variable increase of platelets and myeloid cells [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/80\" class=\"abstract_t\">80</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polycythemia-vera\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of polycythemia vera&quot;</a>.)</p><p>Major progress in elucidating the identity of the affected gene(s) and the nature of the disease-causing mutation responsible for PV was made in 2005 (ie, the <em>JAK2 </em>V617F mutation) [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/81,82\" class=\"abstract_t\">81,82</a>]. The role of mutant <em>JAK2</em> in PV will be discussed here.</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Clonality</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polycythemia vera arises from a single hematopoietic progenitor; as a result, virtually all of the vast majority of the circulating myeloid cells are clonal in origin [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/83,84\" class=\"abstract_t\">83,84</a>]. The mutational event leading to clonal myeloid expansion in PV affects the pluripotent stem cell, since a variable proportion of B-lymphocytes are a part of the PV clone. However, the majority of T cells and natural killer cells remain polyclonal [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/85\" class=\"abstract_t\">85</a>]. These observations provided a background for studies designed to characterize the primary PV defect.</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">In vitro responses of PV progenitor cells</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The first in vitro abnormality in PV progenitor cells was the observation that these cells form erythroid colonies in the absence of exogenous EPO, a phenomenon not observed in progenitor cells from normal subjects [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/86\" class=\"abstract_t\">86</a>]. This observation has been used as a diagnostic assay to help distinguish PV from other causes of polycythemia [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/19,87-89\" class=\"abstract_t\">19,87-89</a>]. The presence of erythroid colonies in the absence of exogenous EPO, variously called spontaneous, EPO-independent, or endogenous erythroid colonies (EECs), is the hallmark of PV. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polycythemia-vera\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of polycythemia vera&quot;</a>.)</p><p>The measurement of EEC is largely restricted to research laboratories that are especially interested in PV and hematopoiesis. However, where available, this test can be readily performed on cultures of peripheral blood progenitor cells; bone marrow aspiration is not required [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/1,89-91\" class=\"abstract_t\">1,89-91</a>]. The erythroid colony assay is a useful tool for distinguishing PV from secondary polycythemias, and has helped characterize primary familial and congenital polycythemia (PFCP) as a separate disease [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/16,75,92\" class=\"abstract_t\">16,75,92</a>]. In PV, EECs form in the absence of added EPO in serum-containing tissue cultures, whereas no or few EEC are present in PFCP or Chuvash polycythemia, conditions in which the erythroid progenitors are hypersensitive to the presence of EPO. In addition, neutralizing antibodies directed against EPO or the EPOR eliminate or markedly inhibit erythroid colony formation in PFCP and normal subjects, but not EEC in PV [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/18,93\" class=\"abstract_t\">18,93</a>].</p><p>Based upon these observations and on our experience, the EEC assay is the most sensitive of all assays used for the diagnosis of PV, especially in those patients lacking the full PV phenotype or the <em>JAK2</em><sup>V617F</sup> mutation [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/94,95\" class=\"abstract_t\">94,95</a>]. Interestingly, some patients presenting with an essential thrombocythemia phenotype have EEC, but on careful follow-up they have typically progressed to PV. The EEC assay is performed in clonogenic cultures containing serum and serum-component proteins. When rigorous serum-free conditions are used, BFU-Es from patients with PV also show markedly increased sensitivity to IGF-I [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/96\" class=\"abstract_t\">96</a>]. This hypersensitivity occurs via the IGF-I receptor, which is hyperphosphorylated under basal conditions [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/97\" class=\"abstract_t\">97</a>]; however, this assay is technically difficult and not routinely available.</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h2\">Other possible mechanisms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Additional pathophysiologic mechanisms leading to PV have been suggested. As an example, previous studies of familial clustering of PV have suggested that loss of heterozygosity (LOH) might play a role in disease pathogenesis. A genome-wide screening for LOH using microsatellite markers with approximately 10 cM average spacing was performed and 9pLOH was detected in approximately 50 percent of PV subjects. This finding represents the most frequent chromosomal lesion described in PV thus far. However, the 9pLOH is due to mitotic recombination (uniparenteral disomy), not from loss of chromosomal material, and thus remains undetectable by cytogenetic analysis [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/95,98\" class=\"abstract_t\">95,98</a>].</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h2\">Familial PV</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are rare instances of a familial incidence of PV [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/99-102\" class=\"abstract_t\">99-102</a>]. In some families, the predisposition for PV is inherited as an autosomal dominant trait with incomplete penetrance. However, clinical PV in these families is acquired as a new mutation, occasionally at a younger age than seen in sporadic PV [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/101\" class=\"abstract_t\">101</a>]. This observation suggests that, at least in these families, the disease may be due to loss of heterozygosity and may result from a combination of an inherited germline mutation followed by a &quot;second hit&quot; somatic mutation that leads to a clonal hematopoiesis.</p><p>Whether the acquired and inherited mutations are due to DNA sequence changes or hereditable changes of <span class=\"nowrap\">DNA/histone</span> confirmation, such as those conferred by <span class=\"nowrap\">methylation/acetylation</span> of DNA and or histone (epigenetic changes) is a subject of active studies. This conclusion is further supported by the fact that the 9pLOH does not segregate in PV families with the PV phenotype, indicating that the molecular defect of PV is caused by more than one <span class=\"nowrap\">genetic/epigenetic</span> event [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/101\" class=\"abstract_t\">101</a>].</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h2\">JAK2 (JAK2V617F) mutation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several studies have shown that <span class=\"nowrap\">JAK/STAT</span> signaling plays a pivotal role in cellular proliferation and cell survival [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/103,104\" class=\"abstract_t\">103,104</a>], in particular in EPO-EPOR signaling in erythropoiesis [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/105\" class=\"abstract_t\">105</a>]. JAK2 deficiency in mice is embryonic lethal due to the absence of definitive erythropoiesis [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/105,106\" class=\"abstract_t\">105,106</a>]. In addition, <span class=\"nowrap\">JAK2-/-</span> fetal liver myeloid progenitors fail to respond to several hematopoietic growth factors including EPO [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/106\" class=\"abstract_t\">106</a>]. <em>JAK2</em> mutations have been reported to be associated with some cases of T-ALL, B-ALL, and atypical CML (chronic neutrophilic leukemia) [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/107,108\" class=\"abstract_t\">107,108</a>], encoding for an oncogenic chimeric protein with constitutive activation of the JAK2 tyrosine kinase (TK) domain. These findings documented that JAK2 has an oncogenic potential.</p><p>Abnormal signaling in PV through JAK2 was first proposed in 2004 [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/109\" class=\"abstract_t\">109</a>], followed by the finding of a single nucleotide <em>JAK2</em> somatic mutation (<em>JAK2 </em>V617F) in the majority of PV patients [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/82\" class=\"abstract_t\">82</a>], confirmed by four separate studies, published in rapid succession [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/110-113\" class=\"abstract_t\">110-113</a>]. This single nucleotide change was shown to emulate many properties of native PV erythroid progenitors, including EPO independence and hypersensitivity of PV erythroid colonies. This mutation dysregulates TK activity by disrupting the JH2 inhibitory regulation of JAK2, allowing the enzyme constitutive tyrosine phosphorylation activity [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/82,110-112\" class=\"abstract_t\">82,110-112</a>]. Mutant JAK2 could then bind to a receptor, recruit, and phosphorylate STATs in the presence of little or no EPO. </p><p>The <em>JAK2 </em>V617F mutation was also shown to be necessary for EPO hypersensitivity of PV progenitors and formation of EEC in in vitro cultures [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/82,110-112\" class=\"abstract_t\">82,110-112</a>]. The most direct evidence connecting this <em>JAK2</em> mutation to PV phenotype was provided when the mutant gene was expressed in mouse models; transplanted mice exhibited a clinical phenotype closely resembling PV [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/82,114-116\" class=\"abstract_t\">82,114-116</a>].</p><p>Interestingly, the elegant transgenic studies with different levels of expression of mutated <em>JAK2 </em>V617F differentiated among ET, PV and PMF phenotypes [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/117\" class=\"abstract_t\">117</a>].</p><p>A duplication of the mutant allele, as a result of previously reported mitotic recombination, resulting in so-called uniparental disomy has been found in a subset of PV myeloid cells and progenitors [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/98\" class=\"abstract_t\">98</a>]. The existence of homozygosity for the <em>JAK2 </em>V617F mutation suggests that it confers a further selective proliferative advantage for the cell [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/118\" class=\"abstract_t\">118</a>]. The <em>JAK2 </em>V617F mutation is acquired preferentially on a specific constitutional JAK2 haplotype named <span class=\"nowrap\">46/1,</span> and this haplotype predisposes to development of both <em>JAK2 </em>V617F as well as <em>JAK2</em> exon 12 mutations (see below) [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/119,120\" class=\"abstract_t\">119,120</a>]. However, this haplotype is not a PV initiating lesion, although its presence makes the acquired <em>JAK2 </em>V617F somatic mutation more likely. While it is of intense theoretical and research interest, the <span class=\"nowrap\">46/1</span> haplotype has no clinically relevant value at the present time and there is no need to establish its presence or absence for optimal care of individual PV patients.</p><p class=\"headingAnchor\" id=\"H1169713\"><span class=\"h2\">JAK2 exon 12 mutations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In some of the rare PV patients who are <em>JAK2 </em>V617F-negative, other <em>JAK2</em> mutations have been identified in exon 12 [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/121,122\" class=\"abstract_t\">121,122</a>]. Unlike the <em>JAK2 </em>V617F mutation, these are heterogeneous and are located within approximately 20 nucleotides and are comprised of missense, stop codon, insertion and deletion mutations. As their allele burden is often low, they are not always easily detectable by conventional techniques such as DNA sequencing [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/123\" class=\"abstract_t\">123</a>]. (See <a href=\"topic.htm?path=overview-of-the-myeloproliferative-neoplasms#H13\" class=\"medical medical_review\">&quot;Overview of the myeloproliferative neoplasms&quot;, section on 'JAK2 mutations'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A significant proportion of patients with primary myelofibrosis or essential thrombocythemia (approximately half) also have the <em>JAK2</em><sup>V617F</sup> mutation [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/82,110-112\" class=\"abstract_t\">82,110-112</a>]. It is not clear whether this mutation acts in concert with other somatic changes, leading to multiple hematopoietic phenotypes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one study, 5 percent of 101 patients with myelodysplastic syndrome and some patients with chronic myelomonocytic and neutrophilic leukemias were also shown to have this mutation [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/124\" class=\"abstract_t\">124</a>]. A separate analysis of 325 patients with various hematological malignancies has confirmed these findings [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/125\" class=\"abstract_t\">125</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>This mutation has also been found in 25 percent of patients with Ph-negative chronic myeloid leukemia, 18 percent of patients with megakaryocytic leukemia, but only in 5 of 10 patients with acute myeloid leukemia and antecedent PV [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/125\" class=\"abstract_t\">125</a>].</p><p/><p>There is growing evidence from studies in patients with sporadic PV as well as familial myeloproliferative neoplasms that the <em>JAK2 </em>V617F mutation is not the PV-originating somatic mutation, but rather represents a late secondary change occurring in a clone initiated by an as yet unidentified genetic change(s) [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/118,126,127\" class=\"abstract_t\">118,126,127</a>]. Nevertheless, <em>JAK2 </em>V617F is clearly the most important discovery in our understanding of PV pathophysiology [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/80\" class=\"abstract_t\">80</a>].</p><p>Several JAK2 inhibitors have been developed and tested in clinical trials and have been demonstrated to be of clinical benefit in PV, and especially in primary and secondary myelofibrosis. The first of these, <a href=\"topic.htm?path=ruxolitinib-drug-information\" class=\"drug drug_general\">ruxolitinib</a>, is FDA approved for use in primary myelofibrosis and also in PV. While it decreases symptoms and partially ameliorates splenomegaly, there is little evidence that it changes the biology of the disease. (See <a href=\"topic.htm?path=overview-of-the-myeloproliferative-neoplasms#H13\" class=\"medical medical_review\">&quot;Overview of the myeloproliferative neoplasms&quot;, section on 'JAK2 mutations'</a> and <a href=\"topic.htm?path=management-of-primary-myelofibrosis#H2068293952\" class=\"medical medical_review\">&quot;Management of primary myelofibrosis&quot;, section on 'Ruxolitinib'</a>.)</p><p class=\"headingAnchor\" id=\"H1169732\"><span class=\"h2\">Additional genetic features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As described above, the vast majority of patients with PV will have a <em>JAK2</em> mutation involving either exon 14 or 12. However, <em>JAK2</em> mutations are also present in other myeloproliferative neoplasms with distinct clinical phenotypes (eg, essential thrombocythemia and primary myelofibrosis) and do not explain the heterogeneity of prognosis among patients with PV. Potential mechanisms for this phenotypic variation include mutations in additional genes, variability in the expression of alternative genes, and epigenetic modification.</p><p>The impact of other genes on PV pathogenesis and phenotype was suggested in a study that performed gene expression profiling (GEP) of CD34+ peripheral blood cells from 19 patients with <em>JAK2 </em>V617F mutated PV and compared it with that of growth factor mobilized CD34+ cells from healthy men and women [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/128\" class=\"abstract_t\">128</a>]. Differences between patterns of gene expression in men and women with PV were used to narrow the analysis to genes more likely to be disease-related.</p><p>Further study is needed to clarify the role of these genes in the pathogenesis of PV, whether these genes may be targeted as part of disease management, and to confirm the prognostic value of gene expression in other cohorts.</p><p>Additional mutations that are encountered with moderate frequency in PV and other Philadelphia chromosome negative myeloproliferative neoplasms include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mutations of genes that often facilitate<em> </em>JAK2 or STAT5 signal transduction, such as: <em>LNK,</em> <em>TET2</em>, <em>CBL</em> [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/129,130\" class=\"abstract_t\">129,130</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mutations of genes that modulate epigenetic composition of genomic DNA (DNA and histone methylation and histone acetylation): <em>EZH2, TET2, ASXL1, JAK2</em> [<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/130,131\" class=\"abstract_t\">130,131</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mutations in genes of the spliceosome machinery: <em>SF3B1, SRSF2, U2AF1 </em>[<a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/130,132,133\" class=\"abstract_t\">130,132,133</a>]</p><p/><p>These mutations have little diagnostic impact, owing to both their low specificity and frequency. However, they have a prognostic role, as shown for <em>EZH2</em> in primary myelofibrosis and p53 alterations at the time of leukemic transformation.</p><p class=\"headingAnchor\" id=\"H5555814\"><span class=\"h1\">SUMMARY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Congenital polycythemias are conditions associated with life-long increases in red blood cell mass secondary to the stimulation of erythropoiesis by mutations that affect the interaction of hemoglobin with oxygen or the various components of the hypoxia-sensing pathway (<a href=\"image.htm?imageKey=HEME%2F53801\" class=\"graphic graphic_figure graphicRef53801 \">figure 2</a>). (See <a href=\"#H2\" class=\"local\">'Regulation of erythropoiesis'</a> above.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alterations in hemoglobin oxygen affinity &ndash; These include high oxygen affinity hemoglobin mutants, congenital methemoglobinemia, and 2,3-bisphosphoglycerate deficiency. (See <a href=\"#H13\" class=\"local\">'Other polycythemias with defined molecular lesions'</a> above and <a href=\"topic.htm?path=genetic-disorders-of-hemoglobin-oxygen-affinity\" class=\"medical medical_review\">&quot;Genetic disorders of hemoglobin oxygen affinity&quot;</a> and <a href=\"topic.htm?path=genetics-and-pathogenesis-of-methemoglobinemia\" class=\"medical medical_review\">&quot;Genetics and pathogenesis of methemoglobinemia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alterations in hypoxia sensing &ndash; These include mutations involving the von Hippel Lindau gene (Chuvash polycythemia) or the more rare mutations of <em>EGLN1</em> (proline hydroxylase 2) or <em>EPAS1</em> (hypoxia inducible factor 2). (See <a href=\"#H8\" class=\"local\">'Congenital polycythemias with augmented hypoxia sensing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Polycythemias with undefined lesions &ndash; These include the autosomal dominant and recessive familial polycythemias and familial polycythemia vera. Alterations of the erythropoietin receptor have been documented in some families, but in most cases the mechanism is unknown. (See <a href=\"#H18\" class=\"local\">'Polycythemias with incompletely defined molecular lesions'</a> above and <a href=\"#H25\" class=\"local\">'Familial PV'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/1\" class=\"nounderline abstract_t\">Eaves CJ, Eaves AC. Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. Blood 1978; 52:1196.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/2\" class=\"nounderline abstract_t\">Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83:59.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/3\" class=\"nounderline abstract_t\">Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292:468.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/4\" class=\"nounderline abstract_t\">Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292:464.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/5\" class=\"nounderline abstract_t\">Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med 2011; 365:537.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/6\" class=\"nounderline abstract_t\">Franke K, Gassmann M, Wielockx B. Erythrocytosis: the HIF pathway in control. Blood 2013; 122:1122.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/7\" class=\"nounderline abstract_t\">Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92:5510.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/8\" class=\"nounderline abstract_t\">Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270:1230.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/9\" class=\"nounderline abstract_t\">Yoon D, Ponka P, Prchal JT. Hypoxia. 5. Hypoxia and hematopoiesis. Am J Physiol Cell Physiol 2011; 300:C1215.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/10\" class=\"nounderline abstract_t\">Semenza GL. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 2009; 114:2015.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/11\" class=\"nounderline abstract_t\">Jones SS, D'Andrea AD, Haines LL, Wong GG. Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood 1990; 76:31.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/12\" class=\"nounderline abstract_t\">Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990; 248:378.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/13\" class=\"nounderline abstract_t\">D'Andrea AD, Yoshimura A, Youssoufian H, et al. The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol 1991; 11:1980.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/14\" class=\"nounderline abstract_t\">Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993; 74:227.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/15\" class=\"nounderline abstract_t\">Klingm&uuml;ller U, Lorenz U, Cantley LC, et al. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995; 80:729.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/16\" class=\"nounderline abstract_t\">Gregg XT, Prchal JT. Erythropoietin receptor mutations and human disease. Semin Hematol 1997; 34:70.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/17\" class=\"nounderline abstract_t\">Arcasoy MO, Degar BA, Harris KW, Forget BG. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood 1997; 89:4628.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/18\" class=\"nounderline abstract_t\">Kralovics R, Indrak K, Stopka T, et al. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 1997; 90:2057.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/19\" class=\"nounderline abstract_t\">Prchal JT. Classification and molecular biology of polycythemias (erythrocytoses) and thrombocytosis. Hematol Oncol Clin North Am 2003; 17:1151.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/20\" class=\"nounderline abstract_t\">Sawada K, Krantz SB, Dessypris EN, et al. Human colony-forming units-erythroid do not require accessory cells, but do require direct interaction with insulin-like growth factor I and/or insulin for erythroid development. J Clin Invest 1989; 83:1701.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/21\" class=\"nounderline abstract_t\">Correa PN, Axelrad AA. Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium: role of insulinlike growth factor 1. Blood 1991; 78:2823.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/22\" class=\"nounderline abstract_t\">Shih LY, Huang JY, Lee CT. Insulin-like growth factor I plays a role in regulating erythropoiesis in patients with end-stage renal disease and erythrocytosis. J Am Soc Nephrol 1999; 10:315.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/23\" class=\"nounderline abstract_t\">Perazella M, McPhedran P, Kliger A, et al. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. Am J Kidney Dis 1995; 26:495.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/24\" class=\"nounderline abstract_t\">Julian BA, Brantley RR Jr, Barker CV, et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998; 9:1104.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/25\" class=\"nounderline abstract_t\">Gossmann J, Th&uuml;rmann P, Bachmann T, et al. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 1996; 50:973.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/26\" class=\"nounderline abstract_t\">Dhondt AW, Vanholder RC, Ringoir SM. Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients. Nephrol Dial Transplant 1995; 10:2107.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/27\" class=\"nounderline abstract_t\">Mrug M, Stopka T, Julian BA, et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100:2310.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/28\" class=\"nounderline abstract_t\">Marrero MB, Schieffer B, Paxton WG, et al. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 1995; 375:247.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/29\" class=\"nounderline abstract_t\">Semenza GL. Oxygen homeostasis. Wiley Interdiscip Rev Syst Biol Med 2010; 2:336.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/30\" class=\"nounderline abstract_t\">Poliakova LA. [Familial erythrocytosis among the residents of the Chuvash ASSR]. Probl Gematol Pereliv Krovi 1974; 19:30.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/31\" class=\"nounderline abstract_t\">Sergeyeva A, Gordeuk VR, Tokarev YN, et al. Congenital polycythemia in Chuvashia. Blood 1997; 89:2148.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/32\" class=\"nounderline abstract_t\">Pastore YD, Jelinek J, Ang S, et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 2003; 101:1591.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/33\" class=\"nounderline abstract_t\">Perrotta S, Nobili B, Ferraro M, et al. Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel cluster. Blood 2006; 107:514.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/34\" class=\"nounderline abstract_t\">Pastore Y, Jedlickova K, Guan Y, et al. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet 2003; 73:412.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/35\" class=\"nounderline abstract_t\">Percy MJ, McMullin MF, Jowitt SN, et al. Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry. Blood 2003; 102:1097.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/36\" class=\"nounderline abstract_t\">Gordeuk VR, Stockton DW, Prchal JT. Congenital polycythemias/erythrocytoses. Haematologica 2005; 90:109.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/37\" class=\"nounderline abstract_t\">Gordeuk VR, Sergueeva AI, Miasnikova GY, et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 2004; 103:3924.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/38\" class=\"nounderline abstract_t\">Sergueeva AI, Miasnikova GY, Polyakova LA, et al. Complications in children and adolescents with Chuvash polycythemia. Blood 2015; 125:414.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/39\" class=\"nounderline abstract_t\">Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002; 32:614.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/40\" class=\"nounderline abstract_t\">Gordeuk VR, Miasnikova GY, Sergueeva AI, et al. Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression. Blood 2011; 118:5278.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/41\" class=\"nounderline abstract_t\">Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117:1926.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/42\" class=\"nounderline abstract_t\">Sergueeva A, Miasnikova G, Shah BN, et al. Prospective study of thrombosis and thrombospondin-1 expression in Chuvash polycythemia. Haematologica 2017; 102:e166.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/43\" class=\"nounderline abstract_t\">Zhou AW, Knoche EM, Engle EK, et al. Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia. N Engl J Med 2016; 375:494.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/44\" class=\"nounderline abstract_t\">Ang SO, Chen H, Gordeuk VR, et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis 2002; 28:57.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/45\" class=\"nounderline abstract_t\">Ladroue C, Hoogewijs D, Gad S, et al. Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. Haematologica 2012; 97:9.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/46\" class=\"nounderline abstract_t\">Tomasic NL, Piterkova L, Huff C, et al. The phenotype of polycythemia due to Croatian homozygous VHL (571C&gt;G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C&gt;T:R200W). Haematologica 2013; 98:560.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/47\" class=\"nounderline abstract_t\">Lanikova L, Lorenzo F, Yang C, et al. Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer. Blood 2013; 121:3918.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/48\" class=\"nounderline abstract_t\">Lorenzo FR, Yang C, Lanikova L, et al. Novel compound VHL heterozygosity (VHL T124A/L188V) associated with congenital polycythaemia. Br J Haematol 2013; 162:851.</a></li><li class=\"breakAll\">Prchal JT. Clinical manifestations and classification of erythrocyte disorders. In: Williams Hematology, 8th ed, Kaushansky K, Lichtman MA, Kipps TJ, et al (Eds), McGraw Hill, New York 2010. p.455.</li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/50\" class=\"nounderline abstract_t\">Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A 2006; 103:654.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/51\" class=\"nounderline abstract_t\">Albiero E, Ruggeri M, Fortuna S, et al. Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Haematologica 2012; 97:123.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/52\" class=\"nounderline abstract_t\">Hsieh MM, Linde NS, Wynter A, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 2007; 110:2140.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/53\" class=\"nounderline abstract_t\">Minamishima YA, Moslehi J, Bardeesy N, et al. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 2008; 111:3236.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/54\" class=\"nounderline abstract_t\">Takeda K, Aguila HL, Parikh NS, et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 2008; 111:3229.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/55\" class=\"nounderline abstract_t\">Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010; 21:2151.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/56\" class=\"nounderline abstract_t\">Querbes W, Bogorad RL, Moslehi J, et al. Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood 2012; 120:1916.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/57\" class=\"nounderline abstract_t\">Ladroue C, Carcenac R, Leporrier M, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 2008; 359:2685.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/58\" class=\"nounderline abstract_t\">Lorenzo FR, Huff C, Myllym&auml;ki M, et al. A genetic mechanism for Tibetan high-altitude adaptation. Nat Genet 2014; 46:951.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/59\" class=\"nounderline abstract_t\">Percy MJ, Furlow PW, Lucas GS, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 2008; 358:162.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/60\" class=\"nounderline abstract_t\">Percy MJ, Beer PA, Campbell G, et al. Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood 2008; 111:5400.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/61\" class=\"nounderline abstract_t\">Gale DP, Harten SK, Reid CD, et al. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation. Blood 2008; 112:919.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/62\" class=\"nounderline abstract_t\">Perrotta S, Stiehl DP, Punzo F, et al. Congenital erythrocytosis associated with gain-of-function HIF2A gene mutations and erythropoietin levels in the normal range. Haematologica 2013; 98:1624.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/63\" class=\"nounderline abstract_t\">Eltzschig HK, El Kasmi KC, Eckle T. The HIF2A gene in familial erythrocytosis. N Engl J Med 2008; 358:1965.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/64\" class=\"nounderline abstract_t\">Zhuang Z, Yang C, Lorenzo F, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 2012; 367:922.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/65\" class=\"nounderline abstract_t\">Yang C, Sun MG, Matro J, et al. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood 2013; 121:2563.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/66\" class=\"nounderline abstract_t\">Pacak K, Jochmanova I, Prodanov T, et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol 2013; 31:1690.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/67\" class=\"nounderline abstract_t\">Lorenzo FR, Yang C, Ng Tang Fui M, et al. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl) 2013; 91:507.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/68\" class=\"nounderline abstract_t\">Agarwal N, Mojica-Henshaw MP, Simmons ED, et al. Familial polycythemia caused by a novel mutation in the beta globin gene: essential role of P50 in evaluation of familial polycythemia. Int J Med Sci 2007; 4:232.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/69\" class=\"nounderline abstract_t\">Lichtman MA, Murphy MS, Adamson JW. Detection of mutant hemoglobins with altered affinity for oxygen. A simplified technique. Ann Intern Med 1976; 84:517.</a></li><li class=\"breakAll\">Agarwal N, Nagel RL, Prchal JT. Dyshemoglobinemias. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, 2nd ed, Steinberg M (Ed), Cambridge UP, Cambridge 2009. p.607.</li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/71\" class=\"nounderline abstract_t\">Rosa R, Prehu MO, Beuzard Y, Rosa J. The first case of a complete deficiency of diphosphoglycerate mutase in human erythrocytes. J Clin Invest 1978; 62:907.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/72\" class=\"nounderline abstract_t\">Galacteros F, Rosa R, Prehu MO, et al. [Diphosphoglyceromutase deficiency: new cases associated with erythrocytosis]. Nouv Rev Fr Hematol 1984; 26:69.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/73\" class=\"nounderline abstract_t\">Lemarchandel V, Joulin V, Valentin C, et al. Compound heterozygosity in a complete erythrocyte bisphosphoglycerate mutase deficiency. Blood 1992; 80:2643.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/74\" class=\"nounderline abstract_t\">Emanuel PD, Eaves CJ, Broudy VC, et al. Familial and congenital polycythemia in three unrelated families. Blood 1992; 79:3019.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/75\" class=\"nounderline abstract_t\">Juvonen E, Ikkala E, Fyhrquist F, Ruutu T. Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood 1991; 78:3066.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/76\" class=\"nounderline abstract_t\">Huang LJ, Shen YM, Bulut GB. Advances in understanding the pathogenesis of primary familial and congenital polycythaemia. Br J Haematol 2010; 148:844.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/77\" class=\"nounderline abstract_t\">Damen JE, Krosl J, Morrison D, et al. The hyperresponsiveness of cells expressing truncated erythropoietin receptors is contingent on insulin-like growth factor-1 in fetal calf serum. Blood 1998; 92:425.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/78\" class=\"nounderline abstract_t\">Divoky V, Liu Z, Ryan TM, et al. Mouse model of congenital polycythemia: Homologous replacement of murine gene by mutant human erythropoietin receptor gene. Proc Natl Acad Sci U S A 2001; 98:986.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/79\" class=\"nounderline abstract_t\">Kralovics R, Prchal JT. Genetic heterogeneity of primary familial and congenital polycythemia. Am J Hematol 2001; 68:115.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/80\" class=\"nounderline abstract_t\">Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355:2452.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/81\" class=\"nounderline abstract_t\">Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006; 107:4214.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/82\" class=\"nounderline abstract_t\">James C, Ugo V, Le Cou&eacute;dic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/83\" class=\"nounderline abstract_t\">Adamson JW, Fialkow PJ, Murphy S, et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976; 295:913.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/84\" class=\"nounderline abstract_t\">Swierczek S, Lima LT, Tashi T, et al. Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms. Leukemia 2015; 29:2432.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/85\" class=\"nounderline abstract_t\">Prchal JT. Polycythemia vera and other primary polycythemias. Curr Opin Hematol 2005; 12:112.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/86\" class=\"nounderline abstract_t\">Prchal JF, Axelrad AA. Letter: Bone-marrow responses in polycythemia vera. N Engl J Med 1974; 290:1382.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/87\" class=\"nounderline abstract_t\">Weinberg RS. In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders. Semin Hematol 1997; 34:64.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/88\" class=\"nounderline abstract_t\">Westwood NB, Pearson TC. Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Leuk Lymphoma 1996; 22 Suppl 1:95.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/89\" class=\"nounderline abstract_t\">Shih LY, Lee CT, See LC, et al. In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia. Eur J Clin Invest 1998; 28:569.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/90\" class=\"nounderline abstract_t\">Shih LY, Lee CT. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood 1994; 83:744.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/91\" class=\"nounderline abstract_t\">Zanjani ED, Lutton JD, Hoffman R, Wasserman LR. Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin. J Clin Invest 1977; 59:841.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/92\" class=\"nounderline abstract_t\">Prchal JT, Crist WM, Goldwasser E, et al. Autosomal dominant polycythemia. Blood 1985; 66:1208.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/93\" class=\"nounderline abstract_t\">Fisher MJ, Prchal JF, Prchal JT, D'Andrea AD. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood 1994; 84:1982.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/94\" class=\"nounderline abstract_t\">Liu E, Jelinek J, Pastore YD, et al. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003; 101:3294.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/95\" class=\"nounderline abstract_t\">Kralovics R, Buser AS, Teo SS, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003; 102:1869.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/96\" class=\"nounderline abstract_t\">Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood 1994; 83:99.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/97\" class=\"nounderline abstract_t\">Mirza AM, Ezzat S, Axelrad AA. Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro. Blood 1997; 89:1862.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/98\" class=\"nounderline abstract_t\">Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30:229.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/99\" class=\"nounderline abstract_t\">Miller RL, Purvis JD 3rd, Weick JK. Familial polycythemia vera. Cleve Clin J Med 1989; 56:813.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/100\" class=\"nounderline abstract_t\">Brubaker LH, Wasserman LR, Goldberg JD, et al. Increased prevalence of polycythemia vera in parents of patients on polycythemia vera study group protocols. Am J Hematol 1984; 16:367.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/101\" class=\"nounderline abstract_t\">Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003; 102:3793.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/102\" class=\"nounderline abstract_t\">Tashi T, Swierczek S, Prchal JT. Familial MPN Predisposition. Curr Hematol Malig Rep 2017; 12:442.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/103\" class=\"nounderline abstract_t\">Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3:651.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/104\" class=\"nounderline abstract_t\">Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol 2006; 134:366.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/105\" class=\"nounderline abstract_t\">Neubauer H, Cumano A, M&uuml;ller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998; 93:397.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/106\" class=\"nounderline abstract_t\">Damen JE, Wakao H, Miyajima A, et al. Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation. EMBO J 1995; 14:5557.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/107\" class=\"nounderline abstract_t\">Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278:1309.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/108\" class=\"nounderline abstract_t\">Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997; 90:2535.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/109\" class=\"nounderline abstract_t\">Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004; 32:179.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/110\" class=\"nounderline abstract_t\">Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/111\" class=\"nounderline abstract_t\">Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/112\" class=\"nounderline abstract_t\">Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/113\" class=\"nounderline abstract_t\">Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280:22788.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/114\" class=\"nounderline abstract_t\">Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107:4274.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/115\" class=\"nounderline abstract_t\">Lacout C, Pisani DF, Tulliez M, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108:1652.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/116\" class=\"nounderline abstract_t\">Akada H, Yan D, Zou H, et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010; 115:3589.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/117\" class=\"nounderline abstract_t\">Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111:3931.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/118\" class=\"nounderline abstract_t\">Bellann&eacute;-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108:346.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/119\" class=\"nounderline abstract_t\">Pietra D, Casetti I, Da Vi&agrave; MC, et al. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. Am J Hematol 2012; 87:746.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/120\" class=\"nounderline abstract_t\">Wang L, Swierczek SI, Lanikova L, et al. The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera. Leukemia 2014; 28:938.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/121\" class=\"nounderline abstract_t\">Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356:459.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/122\" class=\"nounderline abstract_t\">Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008; 111:1686.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/123\" class=\"nounderline abstract_t\">Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011; 86:668.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/124\" class=\"nounderline abstract_t\">Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both &quot;atypical&quot; myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106:1207.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/125\" class=\"nounderline abstract_t\">Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G&gt;T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106:3370.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/126\" class=\"nounderline abstract_t\">Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108:1377.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/127\" class=\"nounderline abstract_t\">Rumi E, Passamonti F, Pietra D, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 2006; 107:2206.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/128\" class=\"nounderline abstract_t\">Spivak JL, Considine M, Williams DM, et al. Two clinical phenotypes in polycythemia vera. N Engl J Med 2014; 371:808.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/129\" class=\"nounderline abstract_t\">Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011; 118:1723.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/130\" class=\"nounderline abstract_t\">Wang L, Swierczek SI, Drummond J, et al. Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. Leukemia 2014; 28:935.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/131\" class=\"nounderline abstract_t\">Vannucchi AM, Biamonte F. Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica 2011; 96:1398.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/132\" class=\"nounderline abstract_t\">Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119:3203.</a></li><li><a href=\"https://www.uptodate.com/contents/molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera/abstract/133\" class=\"nounderline abstract_t\">Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012; 119:4480.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7106 Version 21.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H5555814\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">REGULATION OF ERYTHROPOIESIS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Erythropoietin</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Oxygen sensor</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Erythropoietin receptor</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Insulin-like growth factor-I</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Angiotensin II</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">CONGENITAL POLYCYTHEMIAS WITH AUGMENTED HYPOXIA SENSING</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Chuvash polycythemia</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">von Hippel Lindau gene mutation</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">EGLN1 gene mutations</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">EPAS1 (hypoxia inducible factor 2) gene mutations</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">OTHER POLYCYTHEMIAS WITH DEFINED MOLECULAR LESIONS</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">High oxygen affinity hemoglobin mutants</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Congenital methemoglobinemia</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">2,3-bisphosphoglycerate deficiency</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Primary familial and congenital polycythemia</a></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">POLYCYTHEMIAS WITH INCOMPLETELY DEFINED MOLECULAR LESIONS</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">POLYCYTHEMIA VERA</a><ul><li><a href=\"#H20\" id=\"outline-link-H20\">Clonality</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">In vitro responses of PV progenitor cells</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">Other possible mechanisms</a></li><li><a href=\"#H25\" id=\"outline-link-H25\">Familial PV</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">JAK2 (JAK2V617F) mutation</a></li><li><a href=\"#H1169713\" id=\"outline-link-H1169713\">JAK2 exon 12 mutations</a></li><li><a href=\"#H1169732\" id=\"outline-link-H1169732\">Additional genetic features</a></li></ul></li><li><a href=\"#H5555814\" id=\"outline-link-H5555814\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"HEME/7106|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/70092\" class=\"graphic graphic_figure\">- Regulation of erythropoiesis</a></li><li><a href=\"image.htm?imageKey=HEME/53801\" class=\"graphic graphic_figure\">- Oxygen sensor model</a></li><li><a href=\"image.htm?imageKey=HEME/81216\" class=\"graphic graphic_figure\">- Hemoglobin oxygen dissociation curve</a></li></ul></li><li><div id=\"HEME/7106|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/76036\" class=\"graphic graphic_table\">- Causes of erythrocytosis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-methemoglobinemia\" class=\"medical medical_review\">Clinical features, diagnosis, and treatment of methemoglobinemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polycythemia-vera\" class=\"medical medical_review\">Clinical manifestations and diagnosis of polycythemia vera</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-approach-to-the-patient-with-polycythemia\" class=\"medical medical_review\">Diagnostic approach to the patient with polycythemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=erythrocytosis-following-renal-transplantation\" class=\"medical medical_review\">Erythrocytosis following renal transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genetic-disorders-of-hemoglobin-oxygen-affinity\" class=\"medical medical_review\">Genetic disorders of hemoglobin oxygen affinity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genetics-and-pathogenesis-of-methemoglobinemia\" class=\"medical medical_review\">Genetics and pathogenesis of methemoglobinemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=introduction-to-recombinant-hematopoietic-growth-factors\" class=\"medical medical_review\">Introduction to recombinant hematopoietic growth factors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-primary-myelofibrosis\" class=\"medical medical_review\">Management of primary myelofibrosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=molecular-biology-and-pathogenesis-of-von-hippel-lindau-disease\" class=\"medical medical_review\">Molecular biology and pathogenesis of von Hippel-Lindau disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-myeloproliferative-neoplasms\" class=\"medical medical_review\">Overview of the myeloproliferative neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=regulation-of-erythropoiesis\" class=\"medical medical_review\">Regulation of erythropoiesis</a></li></ul></div></div>","javascript":null}